The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.

<h4>Objective</h4>Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified. The aim of this study was to investigate the factors that may link pioglitazone to bladder cancer.<h4>Materials and methods</h4&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mei-Yueh Lee, Pi-Jung Hsiao, Yi-Hsin Yang, Kun-Der Lin, Shyi-Jang Shin
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2b71f4178a23488ea4e1a6c1de0baafd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b71f4178a23488ea4e1a6c1de0baafd
record_format	dspace
spelling	oai:doaj.org-article:2b71f4178a23488ea4e1a6c1de0baafd2021-11-18T08:38:00ZThe association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.1932-620310.1371/journal.pone.0085479https://doaj.org/article/2b71f4178a23488ea4e1a6c1de0baafd2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24427312/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified. The aim of this study was to investigate the factors that may link pioglitazone to bladder cancer.<h4>Materials and methods</h4>In total, 34,970 study subjects were identified from the National Health Insurance Research Database in 2003 with follow-up from 2005 to 2009. The demographic characteristics of patients who had used and had never used pioglitazone, including age, sex, diabetes duration, urinary tract disease, nephropathy, bladder cancer, and cumulative dose and duration of pioglitazone therapy, were analyzed using the χ2 test. Cox proportional hazard regression models were used to determine the independent effects of pioglitazone on bladder cancer and newly developed chronic kidney disease.<h4>Results</h4>Among 3,497 ever users and 31,473 never users of pioglitazone, the respective incident cases of bladder cancer were 12 (0.4%) and 72 (0.2%), and for newly developed chronic kidney disease 245 (8.1%) and 663 (2.3%), respectively. Ever use of pioglitazone [1.59(1.32-1.91)], cumulative dose of pioglitazone <10,500 mg [1.69 (1.37-2.01)] and >10,500 mg [1.34 (1.04-1.73)], and duration of therapy <12 months [1.68 (1.36-2.08)] and >12 months [1.39 (1.09-1.76)] were associated with the development of chronic kidney disease.<h4>Conclusions</h4>There was no association of pioglitazone use with bladder cancer development, however, there was an association with an increased risk of newly developed chronic kidney disease.Mei-Yueh LeePi-Jung HsiaoYi-Hsin YangKun-Der LinShyi-Jang ShinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e85479 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mei-Yueh Lee Pi-Jung Hsiao Yi-Hsin Yang Kun-Der Lin Shyi-Jang Shin The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
description	<h4>Objective</h4>Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified. The aim of this study was to investigate the factors that may link pioglitazone to bladder cancer.<h4>Materials and methods</h4>In total, 34,970 study subjects were identified from the National Health Insurance Research Database in 2003 with follow-up from 2005 to 2009. The demographic characteristics of patients who had used and had never used pioglitazone, including age, sex, diabetes duration, urinary tract disease, nephropathy, bladder cancer, and cumulative dose and duration of pioglitazone therapy, were analyzed using the χ2 test. Cox proportional hazard regression models were used to determine the independent effects of pioglitazone on bladder cancer and newly developed chronic kidney disease.<h4>Results</h4>Among 3,497 ever users and 31,473 never users of pioglitazone, the respective incident cases of bladder cancer were 12 (0.4%) and 72 (0.2%), and for newly developed chronic kidney disease 245 (8.1%) and 663 (2.3%), respectively. Ever use of pioglitazone [1.59(1.32-1.91)], cumulative dose of pioglitazone <10,500 mg [1.69 (1.37-2.01)] and >10,500 mg [1.34 (1.04-1.73)], and duration of therapy <12 months [1.68 (1.36-2.08)] and >12 months [1.39 (1.09-1.76)] were associated with the development of chronic kidney disease.<h4>Conclusions</h4>There was no association of pioglitazone use with bladder cancer development, however, there was an association with an increased risk of newly developed chronic kidney disease.
format	article
author	Mei-Yueh Lee Pi-Jung Hsiao Yi-Hsin Yang Kun-Der Lin Shyi-Jang Shin
author_facet	Mei-Yueh Lee Pi-Jung Hsiao Yi-Hsin Yang Kun-Der Lin Shyi-Jang Shin
author_sort	Mei-Yueh Lee
title	The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
title_short	The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
title_full	The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
title_fullStr	The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
title_full_unstemmed	The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
title_sort	association of pioglitazone and urinary tract disease in type 2 diabetic taiwanese: bladder cancer and chronic kidney disease.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/2b71f4178a23488ea4e1a6c1de0baafd
work_keys_str_mv	AT meiyuehlee theassociationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT pijunghsiao theassociationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT yihsinyang theassociationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT kunderlin theassociationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT shyijangshin theassociationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT meiyuehlee associationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT pijunghsiao associationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT yihsinyang associationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT kunderlin associationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease AT shyijangshin associationofpioglitazoneandurinarytractdiseaseintype2diabetictaiwanesebladdercancerandchronickidneydisease
_version_	1718421489790746624

The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.

Ejemplares similares